GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » YoY Rev. per Sh. Growth

Lumosa Therapeutics Co (ROCO:6535) YoY Rev. per Sh. Growth : 96.30% (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Lumosa Therapeutics Co YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Lumosa Therapeutics Co's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 was 96.30%.

Lumosa Therapeutics Co's Revenue per Share for the three months ended in Mar. 2025 was NT$0.05.


Lumosa Therapeutics Co YoY Rev. per Sh. Growth Historical Data

The historical data trend for Lumosa Therapeutics Co's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumosa Therapeutics Co YoY Rev. per Sh. Growth Chart

Lumosa Therapeutics Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.72 -35.75 42.61 113.41 -31.71

Lumosa Therapeutics Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.90 -39.53 -61.00 5.26 96.30

Lumosa Therapeutics Co YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Lumosa Therapeutics Co's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(0.239-0.35)/ | 0.35 |
=-31.71 %

Lumosa Therapeutics Co's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2025 )
=(Revenue per Share (Q: Mar. 2025 )-Revenue per Share (Q: Mar. 2024 )) / | Revenue per Share (Q: Mar. 2024 )) |
=(0.053-0.027)/ | 0.027 |
=96.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumosa Therapeutics Co YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Lumosa Therapeutics Co's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumosa Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.

Lumosa Therapeutics Co Headlines

No Headlines